• Accelerating Implementation: Unlocking the Potential of Next-Generation Sequencing

    Bio-IT World | Next-generation sequencing (NGS) has revolutionized molecular biology and served as a universal tool for many research avenues across the spectrum of biology. With the NGS market expanding, three key barriers—time, cost, and expertise—are holding back the potential of NGS and the full impact it could have on society, diagnostics, and precision medicine.

    May 5, 2023

  • Anastasia Christianson on Pfizer’s Approach to AI, ML, and the Digital Age

    Bio-IT World | At Pfizer, AI plays a key role in every step of the drug discovery process, Anastasia Christianson, Global Head of AI, ML, Analytics, and Data at Pfizer, tells Bio-Team co-founder Stan Gloss on the latest episode of the Trends from the Trenches podcast. Christianson will be the opening keynote at the 2023 Bio-IT World Conference & Expo, May 16-18, 2023, in Boston.

    May 4, 2023

  • Novel Mouse Avatars Could Advance Personalized Medicine For Cancer

    Bio-IT World | Up to now, mouse avatars haven’t proven to be particularly good tools for forecasting treatment response in human cancer patients. But new models being generated by an international team of researchers are expected to be far more predictive of what is going to happen with different cohorts of clinical trial participants.

    May 3, 2023

  • Oxford Nanopore Targets Diagnostics, New Products from Vizgen, Agilent, More

    Bio-IT World | Ginkgo Bioworks acquires an adeno-associated virus capsid discovery and engineering platform; Oxford Nanopore Technologies and bioMérieux SA have teamed up bring nanopore sequencing to the infectious disease diagnostics market, and the emergency of Large Language Models ops. Plus, new products from Metabolon, Cytiva, Vizgen, Agilent, and more.

    Apr 27, 2023

  • PEACE Study Offers New Clues About How Cancer Resists Treatment

    Bio-IT World | Research autopsies are nothing new—the use of post-mortem tissues for cancer research has been ongoing since the end of the nineteenth century—but the Cancer Research UK-sponsored PEACE (posthumous evaluation of advanced cancer environment) study stands apart by virtue of its scope and scale. The pan-cancer initiative intends to enroll 500 patients across the country in hopes of understanding cancer evolution, drug resistance and why patients die of their disease.

    Apr 26, 2023